Business
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including
About this update from Tevogen Bio Holdings Inc.
[{"type":"text","content":"Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive.Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen’s lead investor, directors and named executive officers.Company prioritizing long-term stock-based incentive program aligned with company milestones.Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders.Company continues to evaluate acquisitions that could generate over $50 million in combined annual revenue.Company exploring avenues to better reflect value of assets. WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today provided a strategic update regarding its approach to capital management and the continued commitment of its foundational stakeholders. Dr. Manmohan Patel, MD, lead investor in Tevogen, commented, “I continue to have strong conviction in Tevogen’s proprietary ExacTcell™ platform and its potential to deliver meaningful medical innovation. As the Company advances its diversified growth strategy and moves toward operational maturity, I intend to maintain my current shareholdings as a reflection of my long-term confidence in the team, the technology, and the path ahead.” “Tevogen was built on the principle of delivering affordable medical innovations through a highly capital-efficient business model,” said Dr. Ryan Saadi, Founder and CEO of Tevogen Bio. “Based on our current business plan and growth strategy, we do not anticipate utilizing more than one percent of our total authorized shares, including placement through the ATM, over the next twelve months or until the company becomes cash-flow positive.” Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen’s lead investor, directors and named executive officers. Consistent with the January 2026 update, Tevogen continues to prioritize a long-term stock-based incentive program that is strictly aligned with company milestones, including revenue and clinical targets, rather than traditional time-based vesting. Board of D...